Savara Inc. (FRA:YB4P)
Germany · Delayed Price · Currency is EUR 5.30
+0.74 (16.23%)
Last updated: Dec 1, 2025, 8:06 AM CET
Savara Company Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Savara Inc.
| Country | United States |
| Founded | 2007 |
| Industry | Pharmaceutical Preparations |
| Employees | 59 |
| CEO | Matthew Pauls |
Contact Details
Address: 1717 Langhorne Newtown Road Langhorne, Delaware 19047 United States | |
| Phone | 512 614 1848 |
| Website | savarapharma.com |
Stock Details
| Ticker Symbol | YB4P |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew Pauls | Chief Executive Officer |
| David Lowrance | Chief Financial Officer |
| Robert Lutz | Chief Operating Officer |